Effects of VasoCare therapy on the initiation and progression of atherosclerosis (Q28214364)

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Statin trials and goals of cholesterol-lowering therapy after AMI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Treatment challenges in hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Low-density lipoprotein and oxidised low-density lipoprotein: their role in the development of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Immune mechanisms in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Expression of the macrophage scavenger receptor in atheroma. Relationship to immune activation and the T-cell cytokine interferon-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Autohaemotherapy after treatment of blood with ozone. A reappraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

The effect of VAS972 on allergic contact hypersensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Infection as a risk factor for infarction and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

New insights into plaque stabilisation by lipid lowering.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Interleukin-6 exacerbates early atherosclerosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Reduction of atherosclerosis in mice by inhibition of CD40 signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3

Clinical trials of reducing low-density lipoprotein concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900680-3